Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial

Analytical Chemistry

Volumn 84, Issue 20, 2012, Pages 8614-8621

  Sun, Li ^a   Li, Hankun ^a   Willson, Kenneth ^a   Breidinger, Sheila ^a   Rizk, Matthew L ^a   Wenning, Larissa ^a   Woolf, Eric J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCELERATOR MASS SPECTROMETRY; BIOANALYSIS; BIOANALYTICAL ASSAYS; CLINICAL DEVELOPMENT; CLINICAL TRIAL; CONCENTRATION RANGES; DRUG CANDIDATES; HIV-1 INFECTIONS; HIV-1 INTEGRASE; INTEGRASE; ION ELECTROSPRAY; LC-MS/MS; LIMITS OF QUANTIFICATION; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MICRODOSE; MICRODOSING; STANDARD CURVES; ULTRASENSITIVE;

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

DISEASES;

INTEGRASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DOSE CALCULATION; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MALE; METHODOLOGY; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; CHROMATOGRAPHY, LIQUID; DRUG DOSAGE CALCULATIONS; HIV INTEGRASE INHIBITORS; HUMANS; LIMIT OF DETECTION; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84869395719     PISSN: 00032700     EISSN: 15206882     Source Type: Journal    
DOI: 10.1021/ac301581h     Document Type: Article

References (60)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update, 2009, http://data.unaids.org/pub/ Report/2009/jc1700-epi-update-2009-en.pdf. Accessed February, 2012.
2. Hazuda, D.; Iwamoto, M.; Wenning, L. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 377-394.
3. Summa, V.; et al. J. Med. Chem. 2008, 51, 5843-5855.
4. Nguyen, B. T.; et al. Ann. N. Y. Acad. Sci. 2011, 1222, 83-89.
5. Iwamoto, M.; Wenning, L. A.; Petry, A. S.; et al. Clin. Pharmacol. Ther. 2008, 83, 293-299.
6. Kassahun, K.; McIntosh, I.; Cui, D.; Hreniuk, D.; Merschman, S.; Lasseter, K.; Azrolan, N.; Iwamoto, M.; Wagner, J. A.; Wenning, L. A. Drug Metab. Dispos. 2007, 35, 1657-1663.
7. Lennox, J. L.; Dejesus, E.; Lazzarin, A.; et al. Lancet 2009, 374, 796-806.
8. Lennox, J. L.; Dejesus, E.; Berger, D. S.; et al. J. Acquir. Immune Defic. Syndr. 2010, 55, 39-48.
9. Steigbigel, R. T.; Cooper, D. A.; Teppler, H.; et al. Clin. Infect. Dis. 2010, 50, 605-612.
10. Lappin, G.; Garner, C. Nat. Rev. Drug Discov. 2003, 2, 233-240.
11. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry, Investigators, Reviewers: Exploratory IND Studies (ucm078933), 2006; http://www.fda.gov/downloads/Drugs/GuidanceCompilanceRegulatoryInformation/ Guidances/ucm078933.pdf. Accessed March 1, 2011.
12. European Medicines Agency. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose (CPMP/SWP/2599/02/rev 1), 2004; http://www.tga.gov.au/pdf/euguide/swp259902r1en.pdf. Accessed March 1, 2011.
13. Muller, P. Y. Adv. Drug Delivery Rev. 2011, 63, 511-517.
14. Madan, A.; O'Brien, Z.; Wen, J.; O'Brien, C.; et al. Br. J. Clin. Pharmacol. 2009, 67, 288-298.
15. Yamane, N.; Tozuka, Z.; Sugiyama, Y.; Tanimoto, T.; Yamazaki, A.; Kumagai, Y. J. Chromatogr., B 2007, 858, 118-128.
16. Bergstrom, M.; Grahnen, A.; Langstrom, B. Eur. J. Clin. Pharmacol. 2003, 59, 357-366.
17. Lappin, G. Bioanalysis 2010, 2(3), 509-517.
18. Maeda, K.; Sugiyama, Y. Adv. Drug Delivery Rev. 2011, 63, 532-538.
19. Salehpour, M.; Possnert, G.; Bryhni, H. Anal. Chem. 2008, 80(3), 3515-3521.
20. Salehpour, M.; Forsgrad, N.; Possnert, G. Rapid Commun. Mass Spectrom. 2009, 23, 557-563.
21. Garner, R. C. Bioanalysis 2010, 2(3), 429-440.
22. Hopfgarner, G.; Bourgogne, E. Mass Spectrom. Rev. 2003, 22, 195-214.
23. Jemal, M.; Xia, Y. Curr. Drug Metab. 2006, 7, 491-502.
24. Xu, R. N.; Fan, L.; Rieser, M. J.; El-Shourbagy, T. A. J. Pharm. Biomed. Anal. 2007, 44, 342-355.
25. Shah, V. P.; Bansal, S. Bioanalysis 2011, 3(8), 823-827.
26. Yamane, N.; Takami, T.; Tozuka, Z.; et al. Drug Metab. Pharmacokinet. 2009, 24(4), 389-403.
27. Yamane, N.; Tozuka, Z.; Sugiyama, Y.; et al. J. Chromatogr., B 2007, 858, 118-128.
28. Minamide, Y.; Osawa, Y.; Nishida, H.; et al. J. Sep. Sci. 2011, 34, 1590-1598.
29. Heinig, K.; Wirz, T.; Bucheli, F.; Monin, V.; Gloge, A. J. Pharm. Biomed. Anal. 2011, 54, 742-749.
30. Gu, H.; Wang, J.; Aubry, A. F.; Jiang, H.; Zeng, J.; Easter, J.; Wang, J. S.; Dockens, R.; Bifano, M.; Burrell, R.; Arnold, M. E. Anal. Chem. 2012, 84, 4844-4850.
31. Maeda, K.; Sugiyama, Y. Adv. Drug Delivery Rev. 2011, 63, 532-538.
32. Yamane, N.; Tozuka, Z.; Kusama, M.; Maeda, K.; Ikeda, T.; Sugiyama, Y. Pharm. Res. 2011, 28, 1963-1972.
33. Zhang, D.; Fu, Y.; Gale, J. P.; Aubry, A. F.; Arnold, M. E. J. Pharm. Biomed. Anal. 2009, 49, 1027-1033.
34. McLean, M. A.; Tam, C. J.; Baratta, M. T.; Holliman, C. L.; Ings, R. M.; Galluppi, G. R. Drug Dev. Res. 2007, 68, 14-22.
35. Li, F.; Zulkoski, J. P.; Ding, J.; Brown, W.; Addison, T. Rapid Commun. Mass Spectrom. 2010, 24, 2575-2583.
36. Churchwell, M. I.; Twaddle, N. C.; Meeker, L. R.; Doerge, D. R. J. Chromatogr., B 2005, 825, 134-143.
37. Yu, K.; Little, D.; Plumb, R.; Smith, B. Rapid Commun. Mass Spectrom. 2006, 20, 544-552.
38. Novakova, L.; Matysova, L.; Solich, P. Talanta 2006, 68, 908-918.
39. Eeckhaut, A. V.; Maes, K.; Aourz, N.; Smolders, L.; Michotte, Y. Bioanalysis 2011, 3(11), 1271-1285.
40. Meiring, H. D.; Van Der Heeft, E.; Ten Hove, G. J.; De Jong, A. P. J. M. J. Sep. Sci. 2002, 25, 557-568.
41. Wilm, M.; Mann, M. Anal. Chem. 1996, 68, 1-8.
42. Niwa, M. Bioanalysis 2012, 4(2), 213-220.
43. Iwasaki, Y.; Nakano, Y.; Mochizuki, K.; et al. J. Chromatogr., B 2011, 879, 1159-1165.
44. Gao, S.; Zhang, Z. P.; Karnes, H. T. J. Chromatogr., B 2005, 825, 98-110.
45. Merschman, S. A.; Vallano, P. T.; Wenning, L. A.; Matuszewski, B. K.; Woolf, E. J. J. Chromatogr., B 2007, 857, 15-24.
46. Wang, L. Z.; Lee, L. S.; Thuya, W.; et al. J. Mass Spectrom. 2011, 46, 202-208.
47. Ter Heine, R.; Hillebrand, M. J. X.; Rosing, H.; Van Gorp, E. C. M.; Mulder, J. W.; Beijnen, J. H.; Huitema, A. D. R. J. Pharm. Biomed. Anal. 2009, 49, 451-458.
48. Bennetto-Hood C. M. C.; Acosta, E. P. J. Chromatogr., B 2008, 867, 165-171.
49. Kebarle, P.; Verkerk, U. H. Mass Spectrom. Rev. 2009, 28, 898-917.
50. Mansoori, B. A.; Volmer, D. A.; Boyd, R. K. Rapid Commun. Mass Spectrom. 1997, 11, 1120-1130.
51. Wu, Z.; Gao, W.; Phelps, M. A.; Wu, D.; Miller, D. D.; Dalton, J. T. Anal. Chem. 2004, 76, 839-847.
52. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. FDA Guidance for Industry: Bioanalytical Method Validation, Rockville, MD, 2001.
53. Viswanathan, C. T.; Bansal, S.; Booth, B.; et al. AAPS J. 2007, 9, E30-E42.
54. Bansal, S.; De Stefano, A. AAPS J. 2007, 9, E109-E104.
55. Abian, J.; Oosterkamp, A. J.; Gelpi, E J. Mass Spectrom. 1999, 34, 244-254.
56. Liuni, P.; Wilson, D. J. Expert Rev. Proteomics 2011, 8(2), 197-209.
57. Juraschek, R.; Dulcks, T.; Karas, M. J. Am. Soc. Mass Spectrom. 1999, 10, 300-308.
58. Lappin, G.; Kuhnz, H.; Jochemsen, R.; et al. Clin. Pharmacol. Ther. 2006, 80, 203-215.
59. European Microdosing AMS Partnership Programme (EU-MAPP). Outcomes from EUMAPP-A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics, http://www.eumapp. com/.
60. Sugiyama, Y. Drug Metab. Pharmacokinet. 2009, 24, 127-129.